{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:49:36Z","timestamp":1778809776867,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.urolonc.2020.06.024","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T21:59:31Z","timestamp":1595023171000},"page":"173-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Ali","family":"Hajiran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Bracco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan","family":"Zemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2020.06.024_bib0001","first-page":"261","article-title":"The burden of rare cancers in the United States","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.024_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/ijmr.IJMR_915_14","article-title":"Rare cancers: Challenges & issues","volume":"145","author":"Pillai","year":"2017","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.024_bib0003","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.currproblcancer.2015.03.010","article-title":"Epidemiology of penile cancer","volume":"39","author":"Christodoulidou","year":"2015","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.024_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2051415816676740","article-title":"Trends in incidence, mortality and treatment of penile cancer before and after centralisation of penile cancer services in England (1990\u20132009)","volume":"10","author":"Ayres","year":"2017","journal-title":"Journal of Clinical Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.024_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00428-019-02607-8","article-title":"The molecular pathogenesis of penile carcinoma-current developments and understanding","volume":"475","author":"Emmanuel","year":"2019","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.urolonc.2020.06.024_bib0006","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4143\/crt.2005.37.6.319","article-title":"The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis","volume":"37","author":"Yim","year":"2005","journal-title":"Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.urolonc.2020.06.024_bib0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tim.2017.07.007","article-title":"The HPV E6\/E7 oncogenes: Key factors for viral carcinogenesis and therapeutic targets","volume":"26","author":"Hoppe-Seyler","year":"2018","journal-title":"Trends Microbiol"},{"issue":"12","key":"10.1016\/j.urolonc.2020.06.024_bib0008","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1002\/j.1460-2075.1989.tb08570.x","article-title":"HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes","volume":"8","author":"Hawley-Nelson","year":"1989","journal-title":"EMBO J"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2020.06.024_bib0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.1822","article-title":"Human papillomavirus molecular biology and disease association","volume":"25","author":"Doorbar","year":"2015","journal-title":"Rev Med Virol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.06.024_bib0010","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/21645515.2015.1136039","article-title":"Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases","volume":"12","author":"Skeate","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"19","key":"10.1016\/j.urolonc.2020.06.024_bib0011","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"issue":"10008","key":"10.1016\/j.urolonc.2020.06.024_bib0012","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.024_bib0013","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlova","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.024_bib0014","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2020.06.024_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fimmu.2019.00467","article-title":"Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade","volume":"10","author":"Mougel","year":"2019","journal-title":"Front Immunol"},{"issue":"3 Pt 1","key":"10.1016\/j.urolonc.2020.06.024_bib0016","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0190-9622(96)90611-8","article-title":"Squamous cell carcinoma of the penis","volume":"35","author":"Micali","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.06.024_bib0017","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/modpathol.2017.26","article-title":"HPV-negative penile squamous cell carcinoma: disruptive mutations in the TP53 gene are common","volume":"30","author":"Kashofer","year":"2017","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.06.024_bib0018","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2019.37.7_suppl.505","article-title":"Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors","volume":"37","author":"Chahoud","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2020.06.024_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235999","article-title":"Targeting the oncogenic p53 mutants in colorectal cancer and other solid tumors","volume":"20","author":"Li","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.024_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-018-0705-7","article-title":"New therapeutic strategies to treat human cancers expressing mutant p53 proteins","volume":"37","author":"Blandino","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.024_bib0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2008.12.022","article-title":"SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis","volume":"278","author":"Felix","year":"2009","journal-title":"Cancer Lett"},{"issue":"14","key":"10.1016\/j.urolonc.2020.06.024_bib0022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.21037\/atm.2019.06.47","article-title":"High TRIAP1 expression in penile carcinoma is associated with high risk of recurrence and poor survival","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.urolonc.2020.06.024_bib0023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"29","key":"10.1016\/j.urolonc.2020.06.024_bib0024","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.06.024_bib0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1046\/j.1365-2133.2003.05326.x","article-title":"Lichen sclerosus is frequently present in penile squamous cell carcinomas but is not always associated with oncogenic human papillomavirus","volume":"148","author":"Perceau","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.urolonc.2020.06.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/1177271918755391","article-title":"Reactive oxygen species: A key constituent in cancer survival","volume":"13","author":"Kumari","year":"2018","journal-title":"Biomark Insights"},{"key":"10.1016\/j.urolonc.2020.06.024_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12907-015-0003-7","article-title":"SOD2 immunoexpression predicts lymph node metastasis in penile cancer","volume":"15","author":"Termini","year":"2015","journal-title":"BMC Clin Pathol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.06.024_bib0028","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cell.2006.10.003","article-title":"The regulation of INK4\/ARF in cancer and aging","volume":"127","author":"Kim","year":"2006","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.urolonc.2020.06.024_bib0029","first-page":"3689","article-title":"The Pezcoller lecture: cancer cell cycles revisited","volume":"60","author":"Sherr","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2020.06.024_bib0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00428-010-1007-4","article-title":"Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas","volume":"458","author":"Poetsch","year":"2011","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1016\/j.urolonc.2020.06.024_bib0031","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1096\/fasebj.7.10.8393818","article-title":"Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes","volume":"7","author":"Vousden","year":"1993","journal-title":"FASEB J"},{"issue":"10","key":"10.1016\/j.urolonc.2020.06.024_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205350","article-title":"P16INK4a expression in patients with penile cancer","volume":"13","author":"Martins","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.024_bib0033","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/1078-0432.CCR-1032-3","article-title":"Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis","volume":"10","author":"Golijanin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.urolonc.2020.06.024_bib0034","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","article-title":"Cyclooxygenase in biology and disease","volume":"12","author":"Dubois","year":"1998","journal-title":"FASEB J"},{"key":"10.1016\/j.urolonc.2020.06.024_bib0035","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1172\/JCI127755","article-title":"Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2)","volume":"130","author":"Markosyan","year":"2019","journal-title":"J Clin Invest"},{"issue":"497","key":"10.1016\/j.urolonc.2020.06.024_bib0036","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax9566","article-title":"Coaxing cancer control by modulating COX-2","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.024_bib0037","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjc.6603910","article-title":"Targeting HER proteins in cancer therapy and the role of the non-target HER3","volume":"97","author":"Hsieh","year":"2007","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2020.06.024_bib0038","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.humpath.2013.07.012","article-title":"The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases","volume":"44","author":"Chaux","year":"2013","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.024_bib0039","doi-asserted-by":"crossref","first-page":"e17517","DOI":"10.1371\/journal.pone.0017517","article-title":"Alternative HER\/PTEN\/Akt pathway activation in HPV positive and negative penile carcinomas","volume":"6","author":"Stankiewicz","year":"2011","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.urolonc.2020.06.024_bib0040","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.urolonc.2020.06.024_bib0041","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.024_bib0042","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","article-title":"First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2020.06.024_bib0043","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.12450","article-title":"Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis","volume":"113","author":"Carthon","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.06.024_bib0044","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3389\/fimmu.2018.01253","article-title":"The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma","volume":"9","author":"Ottenhof","year":"2018","journal-title":"Front Immunol"},{"issue":"3 Pt 1","key":"10.1016\/j.urolonc.2020.06.024_bib0045","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","article-title":"Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status","volume":"197","author":"Ottenhof","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.024_bib0046","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4419-1599-3_2","article-title":"FOXP3 and its role in the immune system","volume":"665","author":"Kim","year":"2009","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.024_bib0047","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s13277-014-2864-2","article-title":"Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence","volume":"36","author":"Vassallo","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.024_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.03.063","article-title":"Genomic, pathway network, and immunologic features distinguishing squamous carcinomas","volume":"23","author":"Campbell","year":"2018","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.024_bib0049","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOU.0000000000000640","article-title":"Genetics and penile cancer: recent developments and implications","volume":"29","author":"Chahoud","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2020.06.024_bib0050","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41467-020-15980-9","article-title":"Effective combinatorial immunotherapy for penile squamous cell carcinoma","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:12Z","timestamp":1761042192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920302945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1078143920302945"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.024","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}